Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Jan 2, 2019
Politics & Policy

Part D beneficiaries hit hardest under 2019 price hikes

BioCentury | Aug 8, 2016
Clinical News

Viberzi eluxadoline regulatory update

BioCentury | Jul 22, 2016
Company News

CHMP recommendations include Truvada for PrEP

BioCentury | Jan 18, 2016
Company News

Allergan, Ironwood sales and marketing update

BioCentury | Sep 28, 2015
Company News

Allergan, Ironwood deal

BioCentury | Jun 1, 2015
Clinical News

Viberzi eluxadoline regulatory update

BioCentury | May 28, 2015
Company News

FDA approves pair of IBS therapies

BioCentury | Sep 8, 2014
Clinical News

Eluxadoline regulatory update

BioCentury | Sep 3, 2014
Company News

Priority Review for Actavis' eluxadoline

Items per page:
1 - 10 of 21